Skip to main content
Fig. 2 | Cell Communication and Signaling

Fig. 2

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Fig. 2

Clinical test procedure and c-Met cutoff determination and prevalence analysis using the CELsignia test in a population of HER2 negative breast cancer patients. a Clinical test procedure summary: A 14-gauge to 18-gauge needle biopsy containing about 25 mg of tumor tissue is removed and sent by overnight courier to the Celcuity lab in Minneapolis. After a brief, no passage, culture establishes the viability of the tumor cells, a CELsignia multipathway test is performed using an impedance-based biosensor (96-well format device). Typically, an abnormal signaling report is returned to the requesting physician in less than 14 days. b CELsigniaTest Score distribution density analysis: The likelihood ratio test for the number of components gave the following parameters. For the three-component model, the components 2 (purple) & 3 (blue) means are more than four standard deviations apart. c ROC curve for the three-component fit plots sensitivity versus false positive rate for various cut-off points. Formal significance testing shows that a two-component mixture fits much better than a common normal distribution, and a three-component mixture fits better than two. d False positive rate (blue line) and sensitivity (black line) are presented as a function of the cutoff used

Back to article page